We are proud to announce that under the BioExcel Centre of Excellence (CoE) for Computational Biomolecular Research framework for scientific, societal and industrial impact, two of our partners: Nostrum Biodiscovery, a leading provider of computational drug discovery services, and the Institute for Research in Biomedicine (IRB), have established a collaboration with Meletios Therapeutics, a French biotech company aimed at developing broad spectrum treatments against current and emerging viral infections. 

This partnership will focus on applying High Throughput Virtual Screening (HTVS) services to streamline the drug discovery process using BioExcel core applications. This aims to deliver unparalleled performance in searching vast chemical spaces while utilizing low computational resources, thus increasing the efficiency and accessibility of drug discovery efforts. This innovative technology promises to identify potential drug candidates within weeks, significantly accelerating the discovery pipeline.

Meletios Therapeutics is a French biotechnology company specialized in the research and development of next-generation antiviral treatments. Founded in April 2020 during the first covid-19 pandemic lockdown period, Meletios Therapeutics aims to develop innovative antiviral molecules to treat a wide range of diseases. Meletios Therapeutics is developing complementary approaches to identify compounds with high therapeutic potential in the fight against viral infections. The company is targeting the development of broad-spectrum antiviral treatments capable of treating multiple indications through their innovative mechanism of action. With its unique approach and recognized expertise, Meletios Therapeutics intends to become a world leader in the fight against emerging viral infections.

About: Nostrum Biodiscovery

About: IRB Barcelona